COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?”
Abstract The novel coronavirus which emerged in Wuhan province of China has taken world by surprise. Since been diagnosed in December 2019, it has been termed a “Pandemic” and there is a growing concern in physicians across the globe. As new evidence is emerging, there are various preventative strat...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2020-05-01
|
Series: | The Egyptian Journal of Neurology, Psychiatry and Neurosurgery |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s41983-020-00177-0 |
id |
doaj-28e2e83e17c54a4a8a979cd8dbc634bc |
---|---|
record_format |
Article |
spelling |
doaj-28e2e83e17c54a4a8a979cd8dbc634bc2020-11-25T02:13:05ZengSpringerOpenThe Egyptian Journal of Neurology, Psychiatry and Neurosurgery1687-83292020-05-015611310.1186/s41983-020-00177-0COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?”Salman Mansoor0Siobhan Kelly1Kevin Murphy2Aine Waters3Nauman Saleem Siddiqui4Department of Neurology, Sligo University HospitalDepartment of Neurology, Sligo University HospitalDepartment of Neurology, Sligo University HospitalDepartment of Neurology, Sligo University HospitalDivision of Adult Haematology, Tufts Medical CentreAbstract The novel coronavirus which emerged in Wuhan province of China has taken world by surprise. Since been diagnosed in December 2019, it has been termed a “Pandemic” and there is a growing concern in physicians across the globe. As new evidence is emerging, there are various preventative strategies which are being deployed. Multiple sclerosis patients who are on disease modifying therapies (DMTs) might be at a higher risk of acquiring or a poorer outcome due to their immune status. This review looks at the available evidence in managing this global crisis.http://link.springer.com/article/10.1186/s41983-020-00177-0CoronavirusCOVID-19Multiple sclerosisDisease modifying therapies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Salman Mansoor Siobhan Kelly Kevin Murphy Aine Waters Nauman Saleem Siddiqui |
spellingShingle |
Salman Mansoor Siobhan Kelly Kevin Murphy Aine Waters Nauman Saleem Siddiqui COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?” The Egyptian Journal of Neurology, Psychiatry and Neurosurgery Coronavirus COVID-19 Multiple sclerosis Disease modifying therapies |
author_facet |
Salman Mansoor Siobhan Kelly Kevin Murphy Aine Waters Nauman Saleem Siddiqui |
author_sort |
Salman Mansoor |
title |
COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?” |
title_short |
COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?” |
title_full |
COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?” |
title_fullStr |
COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?” |
title_full_unstemmed |
COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?” |
title_sort |
covid-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?” |
publisher |
SpringerOpen |
series |
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery |
issn |
1687-8329 |
publishDate |
2020-05-01 |
description |
Abstract The novel coronavirus which emerged in Wuhan province of China has taken world by surprise. Since been diagnosed in December 2019, it has been termed a “Pandemic” and there is a growing concern in physicians across the globe. As new evidence is emerging, there are various preventative strategies which are being deployed. Multiple sclerosis patients who are on disease modifying therapies (DMTs) might be at a higher risk of acquiring or a poorer outcome due to their immune status. This review looks at the available evidence in managing this global crisis. |
topic |
Coronavirus COVID-19 Multiple sclerosis Disease modifying therapies |
url |
http://link.springer.com/article/10.1186/s41983-020-00177-0 |
work_keys_str_mv |
AT salmanmansoor covid19pandemicandtheriskofinfectioninmultiplesclerosispatientsondiseasemodifyingtherapieswhatthebleepdoweknow AT siobhankelly covid19pandemicandtheriskofinfectioninmultiplesclerosispatientsondiseasemodifyingtherapieswhatthebleepdoweknow AT kevinmurphy covid19pandemicandtheriskofinfectioninmultiplesclerosispatientsondiseasemodifyingtherapieswhatthebleepdoweknow AT ainewaters covid19pandemicandtheriskofinfectioninmultiplesclerosispatientsondiseasemodifyingtherapieswhatthebleepdoweknow AT naumansaleemsiddiqui covid19pandemicandtheriskofinfectioninmultiplesclerosispatientsondiseasemodifyingtherapieswhatthebleepdoweknow |
_version_ |
1724906390181380096 |